Ann: Dosing begins in Phase I PK trial testing CBD soft-gel, page-5

Trial participants received their first dose on 2 October; second dosing will commence on 9 October, but we have to wait until the beginning of December for results. It was stated in the announcement of enrolment last month that blood samples from the trial will be shipped to Canada for analysis of CBD, TP, T2P and tocopherol (the components of AVE’s TPM formulation), something Paul Gavin also mentioned in last month's Horizon Biotech webinar.

So, this TPM CBD product has undergone pre-clinical in vitro and in vivo testing and optimisation with Bioneer:FARMA in Copenhagen, Denmark; manufacturing of softgel dosage with Catalent in Florida, USA; clinical testing at CMax in Adelaide, Australia and trial blood analysis in Canada.

There has been no information on exactly who is conducting the blood analysis in Canada or why. However Paul Gavin has stated “We’ve got lots of overseas interest in the product.”